Peloton Wealth Strategists’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q3
Sell
-13,336
Closed -$903K 59
2018
Q2
$903K Sell
13,336
-3,683
-22% -$254K 0.65% 52
2018
Q1
$1.23M Sell
17,019
-3,125
-16% -$238K 0.93% 45
2017
Q4
$1.51M Buy
20,144
+112
+0.6% +$8.45K 1.13% 40
2017
Q3
$1.54M Buy
20,032
+1,953
+11% +$147K 1.19% 41
2017
Q2
$1.35M Buy
18,079
+1,116
+7% +$79.1K 1.05% 39
2017
Q1
$1.13M Buy
16,963
+1,004
+6% +$66.9K 0.93% 48
2016
Q4
$1.04M Buy
15,959
+1,060
+7% +$68.8K 0.85% 51
2016
Q3
$1.05M Buy
+14,899
New +$1.09M 0.88% 49
2016
Q1
$967K Buy
14,899
+112
+0.8% +$7.62K 0.82% 50
2015
Q4
$1.14M Sell
14,787
-2,734
-16% -$217K 0.98% 46
2015
Q3
$1.44M Sell
17,521
-2,400
-12% -$214K 1.26% 40
2015
Q2
$1.75M Sell
19,921
-19,139
-49% -$1.76M 1.4% 30
2015
Q1
$3.45M Sell
39,060
-446
-1% -$39.6K 2.68% 4
2014
Q4
$3.28M Sell
39,506
-56
-0.1% -$4.64K 2.49% 5
2014
Q3
$3.34M Buy
39,562
+24,663
+166% +$2M 2.63% 4
2014
Q2
$1.1M Sell
14,899
-25,835
-63% -$2.03M 0.97% 46
2014
Q1
$3.1M Hold
40,734
2.55% 6
2013
Q4
$2.93M Buy
40,734
+781
+2% +$54.3K 2.37% 7
2013
Q3
$2.75M Buy
39,953
+56
+0.1% +$3.71K 2.3% 6
2013
Q2
$2.53M Buy
+39,897
New +$2.6M 2.27% 8

Other funds holding NVS

Peloton Wealth Strategists's NVS Position: Q3 2018 in Review

Peloton Wealth Strategists sold out of Novartis (NVS) in Q3 2018, closing a stake of 13,336 shares — an estimated $903K sold.

Peloton Wealth Strategists first reported a position in NVS in Q2 2013 and held it in 20 quarters. The position peaked at $3.45M in Q1 2015. 1,028 funds tracked by Wall St. Rank hold NVS as of Q3 2018.

  • Peloton Wealth Strategists reported no remaining Novartis position as of Q3 2018 after selling out during the quarter.
  • Peloton Wealth Strategists sold 13,336 Novartis shares in Q3 2018, an estimated $903K.
  • Peloton Wealth Strategists first reported a position in Novartis in Q2 2013 and held it in 20 quarters.
  • Peloton Wealth Strategists's Novartis position peaked at $3.45M in Q1 2015.
  • 1,028 funds tracked by Wall St. Rank held Novartis as of Q3 2018.

Based on Peloton Wealth Strategists's 13F filing for Q3 2018, filed 14 Nov 2018.